Sei Yonezawa, Ph.D.
Institution:

Department of Medical Biochemistry, School of Pharmaceutical Sciences, University ofShizuoka

Position:

Assistant Professor

E-Mail:yonezawa@u-shizuoka-ken.ac.jp

Address:

52-1 Yada, Suruga-ward, Shizuoka-city, Shizuoka 422-8526, Japan
Tel:+81 54-264-5700, FAX: +81 54-264-5705

Education:
Apr. 2004 to Mar. 2007 Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan(Ph.D.)
Apr. 2002 to Mar. 2004 Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan(M. Sc.)
Apr. 1998 to Mar. 2002 School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (B. Sc.)
EmploymentJan. 2019 to present

University of Shizuoka, School of Pharmaceutical Science, Assistant Professor

Apr. 2009 to Dec. 2018

Iwate Medical University, School of Pharmacy, Research Assistant Professor

Apr. 2008 to Mar. 2009

Iwate Medical University, School of Pharmacy, Teaching AssistantApr. 2007 to Mar. 2008

Research Institute International Medical Center of Japan, Postdoctoral fellow

Menbership:
The Pharmaceutical Society of JapanThe Japanese Conference on the Biochemistry of Lipids
Awards:Controlled Release Society travel award (Jul. 2003)
Journal articles1)

Yonezawa S, Abe M, Kawasaki Y, Natori Y, Sugiyama A: Each liver X receptor (LXR) type has adifferent purpose in different situations. Biochem. Biophys. Res. Commun. 508, 92-96 (2019)2)

Ogasawara N, Kudo T, Sato M, Kawasaki Y, Yonezawa S, Takahashi S, Miyagi Y, Natori Y, Sugiyama
A: Reduction of Membrane Protein CRIM1 Decreases E-Cadherin and Increases Claudin-1 and MMPs,
Enhancing the Migration and Invasion of Renal Carcinoma Cells. Biol. Pharm. Bull. 41,604-611 (2018)3)

Shimizu K, Miyauchi H, Urakami T, Yamamura-Ichikawa K, Yonezawa S, Asai T, Oku N: Specificdelivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its
anti-allergic effect. J. Drug Target. 1-29 (2016)

4)

Kawasaki Y, Yokobayashi E, Sakamoto K, Tenma E, Takaki H, Chiba Y, Otashiro T, Ishihara M,
Yonezawa S, Sugiyama A, Natori Y: Angiostatin prevents IL-1β-induced down-regulation of eNOS
expression by inhibiting the NF-κB cascade. J. Pharmacol Sci. 129, 200-2004 (2015)

5)

Ichikawa K, Asai T, Shimizu K, Yonezawa S, Urakami T, Miyauchi H, Kawashima H, Ishida T, Kiwada
H, Oku N: Suppression of immune response by antigen-modified liposomes encapsulating modelagents: A novel strategy for the treatment of allergy. J. Control. Release 167, 284-289 (2013)

6)

Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H,Nango M, Oku N: Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2knockdown. Biochem. Biophys. Res. Commun. 368, 243-248 (2008)

7)

Ichikawa K, Urakami T, Yonezawa S, Miyauchi H, Shimizu K, Asai T, Oku N: Enhanced
desensitization efficacy by liposomal conjugation of a specific antigen. Int. J. Pharm. 336, 391-395(2007)

8)

Yonezawa S, Asai T, Oku N: Effective tumor regression by anti-neovascular therapy in hypovascularorthotopic pancreatic tumor model. J. Control. Release 118, 303-309 (2007)

9)

Siripong P, Yahuafai J, Shimizu K, Ichikawa K, Yonezawa S, Asai T, Kanokmedakul K, Ruchirawat S,Oku N: Antitumor activity of liposomal naphthoquinone esters isolated from thai medicinal plant:
Rhinacanthus nasutus Kurz. Biol. Pharm. Bull. 29, 2279-2283 (2006)10)

Siripong P, Yahuafai J, Shimizu K, Ichikawa K, Yonezawa S, Asai T, Kanokmedakul K, Ruchirawat S,Oku N: Induction of apoptosis in tumor cells by three naphthoquinone esters isolated from thai
medicinal plant: Rhinacanthus nasutus KURZ. Biol. Pharm. Bull. 29, 2070-2076 (2006)

11)

Maeda N, Miyazawa S, Shimizu K, Asai T, Yonezawa S, Kitazawa S, Namba Y, Tsukada H, Oku N:
Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distributionof the active targeting carrier for anticancer drugs. Biol. Pharm. Bull. 29, 1936-1940 (2006)

12)

Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, Namba Y, Oku N: Antiangiogenic
photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific toangiogenic vessels. Biochim. Biophys. Acta 1669, 69-74 (2005)

13)

Takeuchi Y, Ichikawa K, Yonezawa S, Kurohane K, Koishi T, Nango M, Namba Y, Oku N: Intracellulartarget for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation
liposome. J. Control. Release. 97, 231-240 (2004)

14)

Shigeta Y, Imanaka H, Yonezawa S, Oku N, Baba N, Makino T: Suppressed permeation of linoleic acidin a liposomal formulation through reconstructed skin tissue. Biol. Pharm. Bull. 27, 879-882 (2004)

15)

Tamura M, Unno K, Yonezawa S, Hattori K, Nakashima E, Tsukada H, Nakajima M, Oku N: In vivo
trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization.
Life Sci. 75, 575-584 (2004)

16)

Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, Oku N: Antiangiogenic
photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer
Lett. 205, 39-48 (2004)

17)

Takeuchi Y, Kurohane K, Ichikawa K, Yonezawa S, Ori H, Koishi T, Nango M, Oku N: Polycation
liposome enhances the endocytic uptake of photosensitizer into cells in the presence of serum.
Bioconjug. Chem. 14, 790-796 (2003)

18)

Takeuchi Y, Kurohane K, Ichikawa K, Yonezawa S, Nango M, Oku N: Induction of intensive tumor
suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal
photosensitizer. Cancer. 97, 2027-2034 (2003)

Book
Yonezawa S, Asai T, Oku N: Dosal air sac model. Angiogenesis assays, 229-238 John Wiley & Sons,
Ltd (2007)